Comparing two drugs for low platelets from cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a confirmed cancer diagnosis and are receiving chemotherapy, radiation, immunotherapy, or targeted therapy.
- Your platelet count is very low (between 10,000 and 75,000) from your cancer treatment.
- You are generally able to perform daily activities (ECOG score 0-2).
- Your doctor expects you to live at least 12 weeks and continue cancer treatment for at least one more cycle.
- You agree to use reliable birth control during the study if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a new form of romiplostim (a drug that boosts platelets) in breast cancer patients whose platelet counts have dropped due to chemotherapy. It aims to see if it can safely raise platelet levels to reduce bleeding risk and allow chemo to continue.
This trial tests a drug called romiplostim N01 to see if it can increase low platelet counts caused by radiation therapy or radiation combined with other cancer treatments. Platelets help your blood clot, and low levels can be dangerous.
Hear when a new CTIT: Cancer Therapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.